Monoclonal antibodies have become a mainstay in the treatment of patients with relapsing
multiple sclerosis (RMS) and provide some benefit to patients with primary progressive MS …

Across its clinical development program, ocrelizumab demonstrated efficacy in improving
clinical outcomes in multiple sclerosis, including annualized relapse rates and confirmed …

Objective The study was undertaken to assess the impact of B cell depletion on humoral and
cellular immune responses to severe acute respiratory syndrome‐coronavirus 2 (SARS …

Background and Objectives B cell–depleting therapies are highly effective in relapsing-
remitting multiple sclerosis (RRMS) but are associated with increased infection risk and …

The potential impact of disease-modifying therapies (DMTs) for multiple sclerosis (MS) on
COVID-19 vaccination is poorly understood. According to recent observations, the humoral …

CD20 depletion is a risk factor for unfavorable outcomes of COVID-19 in people with MS
(pwMS). Evidence suggests that protective IgG response to mRNA-based vaccines in B cell …

Background Recent studies suggest that extended interval dosing of ocrelizumab, an anti-B
cell therapy, does not affect its clinical effectiveness in most patients with multiple sclerosis …

Background and Objectives Patients with multiple sclerosis (PwMS) receiving extended
dosing of rituximab (RTX) have exhibited no return of disease activity, which suggests that …

Background The immunogenicity of COVID-19 vaccine among patients receiving anti-CD20
monoclonal antibody (Ab) treatment has not been fully investigated. Detectable levels of …

Background Neurologic outcomes in patients with multiple sclerosis (MS) and related
disorders (MSRD) following COVID-19 is not well understood. The objective of this study …